Highland Capital Management Fund Advisors, L.P. Pacira Bio Sciences, Inc. Transaction History

Highland Capital Management Fund Advisors, L.P.

$846 Million
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$51.97 - $63.0 $288,433 - $349,650	-5,550 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$30.8 - $52.47 $36,960 - $62,964	-1,200 Reduced 17.78%	5,550 $291,000
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $269,800 - $481,650	-9,500 Reduced 58.46%	6,750 $226,000
Q3 2019 Nov 14, 2019	BUY	$35.66 - $44.99 $579,475 - $731,087	16,250 New	16,250 $619,000

Others Institutions Holding PCRX

# of Institutions

263

Shares Held

50.4M

Call Options Held

429K

Put Options Held

391K

Black Rock Inc. New York, NY

8.01M
Shares

$156 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

5.3M
Shares

$103 Million
0.0% of portfolio
Pacer Advisors, Inc. Malvern, PA

4.96M
Shares

$96.6 Million
0.18% of portfolio
State Street Corp Boston, MA

2.01M
Shares

$39.2 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.98M
Shares

$38.5 Million
0.05% of portfolio

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.

Account